Copenhagen, April 15th, 2026. gMendel^® today announced the successful closing of its seed funding round and the signing of a strategic investment agreement with Metavallon VC of €1.2M to accelerate the global deployment of its genetic screening technology across Latin America, the Middle East, and Africa.

The agreement follows over a year of rigorous evaluation, including extensive due diligence and consultations with international experts and healthcare professionals, confirming strong confidence in gMendel® ‘s technology and impact potential.

gMendel^® is pioneering an AI-powered, IVD-certified platform that makes genetic screening faster, more accurate, and scalable. By combining genomics with artificial intelligence, the company enables early diagnosis in newborns, reducing misdiagnosis, improving treatment outcomes, and significantly lowering healthcare costs.

With approximately 7 million babies born each year with genetic disorders (most undiagnosed) gMendel^® addresses a critical global gap, particularly in regions where screening programs are still emerging. Its technology allows these healthcare systems to leapfrog directly to next-generation genetic screening.

Recent clinical studies demonstrated outstanding performance, with sensitivity up to 98% and specificity up to 100%, validating the platform’s accuracy and scalability.

Dr. Chris Kyriakidis, gMendel^® CEO and co-founder, said:
“This investment marks a pivotal milestone for gMendel^®. It validates not only our technology, but the urgent global need for scalable genetic screening solutions. Together with Metavallon VC, we are accelerating our mission to make early, accurate diagnosis accessible to every newborn, regardless of geography. By combining genomics and AI, we have the opportunity to fundamentally change how healthcare systems detect and manage genetic disorders, ultimately saving lives while significantly reducing long-term costs.”

George Karantonis, Partner at Metavallon VC, added:
“We believe gMendel^® is uniquely positioned to drive the next generation of genetic screening and improve outcomes at population scale. Having followed the team closely over an extended period, we have been consistently impressed not only by the strength of the technology, but by their commitment and strong internal drive to translate innovation into tangible societal impact. In addition, gMendel^®’s plans to establish a technology development hub in Greece, along with the initiation of discussions with the Greek Ministry of Health for potential adoption of the solution, further strengthen our conviction in the company’s long‑term vision and make this investment even more relevant to our strategy.”

This partnership marks a major milestone in gMendel^®’s mission to reduce infant mortality and transform global healthcare through early, data-driven screening at population scale.

About gMendel^®
gMendel^® is a Denmark-based medical technology company, founded in 2020, focused on transforming genetic diagnostics through scalable, AI-powered screening solutions. Its IVD-certified platform combines advanced genomics and artificial intelligence to enable fast, accurate, and cost-effective detection of genetic disorders in prenatal and newborn care. By making large-scale genetic screening accessible, gMendel^® aims to improve early diagnosis, significantly reduce healthcare costs, and support better patient outcomes. More information: www.g-mendel.com

About Metavallon VC
Metavallon VC is a Greek based venture capital firm that specializes in funding technology startups at the Pre-Seed to Seed+ stages, supporting ambitious entrepreneurs in building transformative businesses across multiple sectors and geographies. With over €70 million in capital under management, Metavallon VC has invested in more than 35 startups since 2018. This specific investment is made through the Metavallon II fund, which is backed by the Hellenic Development Bank of Investments (HDBI), the European Investment Fund (EIF), as well as leading institutional and private investors. More information: www.metavallon.vc